Search

everythinglearnresearchcommunity

for

Search:↓

Certain cells in the adult mouse ear come from cranial neural crest cells, but muscle and hair cells do not.

A specific RNA molecule blocks hair growth by affecting a protein related to hair loss conditions.

N-acetyl-GED may help prevent and partially reverse a process that leads to scarring hair loss.

2011 dermatology discussions highlighted stem cell hair treatments, new lichen planopilaris therapies, skin side effects from cancer drugs, emerging allergens, and the link between food allergies and skin issues.

The RNA AL136131.3 slows down hair growth and speeds up hair loss by affecting sugar breakdown in hair follicles.

MPZL3 protein helps control the size of oil glands and the growth of oil-producing cells in both mice and humans.

Lichen Planopilaris is a hair loss condition best treated early with various medications, including hydroxychloroquine, to prevent permanent baldness.

A 70-year-old woman with a rare skin condition improved after treatment with topical steroids and acitretin.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Sebaceous glands are often preserved and PPARy expression is constant in some cases of Central Centrifugal Cicatricial Alopecia.

New treatments and early diagnosis methods for permanent hair loss due to scar tissue are important for managing its psychological effects.

The Hair India 2010 conference introduced a new hair loss classification and highlighted advanced diagnostic techniques in trichology.

Frontal fibrosing alopecia is a scarring hair loss condition mainly affecting older women, with no known cause and treatments that may help stabilize hair loss.

Human hair follicle organ culture is a useful model for hair research with potential for studying hair biology and testing treatments.

Treatments for permanent hair loss from scarring aim to stop further loss, not regrow hair, and vary by condition, with partial success common.

Type 2 diabetes, bacterial scalp infections, and tight hairstyles like braids and weaves are linked to a higher risk of a scarring hair loss condition in African American women.

The document concludes that proper diagnosis and FDA-approved treatments for different types of hair loss exist, but treatments for severe cases often fail and future improvements may focus on hair follicle stem cells.

Prostaglandin D₂ might be targeted for new male pattern baldness treatments.

Scarring alopecias are complex hair loss disorders that require early treatment to prevent permanent hair loss.

The document concludes that treating PCOS requires a combination of drugs to manage reproductive and metabolic symptoms, with more research needed on combination therapies.

The document concludes that primary scarring alopecias cause permanent hair loss, have unpredictable outcomes, and lack definitive treatments, requiring personalized care.

New treatments for hair loss show promise, but more development is needed, especially for tough cases.

Special and immunohistochemical stains are not routinely needed for diagnosing hair disorders.

Recognize and treat hair loss conditions that mimic androgenetic alopecia by identifying warning signs and using proper tools.

Researchers found a new early sign of Frontal Fibrosing Alopecia that could help avoid misdiagnosis.

Certain gene variations might help protect against insulin resistance and glucose intolerance in people with Polycystic Ovary Syndrome.

Pregnancy right after giving birth in mice lacking IL-10 causes milk that leads to liver issues and hair loss in their babies.

The document concludes that treatments for cicatricial alopecia are not well-supported by evidence, but hair transplantation shows more predictable and satisfactory results.

The document concludes that more research is needed to better understand and treat scarring hair loss conditions.

Frontal Fibrosing Alopecia is a type of hair loss affecting mostly older women, with no agreed best treatment.